Added evidence for emicizumab in children with hemophilia A

Swiss pharma major Roche (SIX: ROG) has announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children of less than 12 years of age with hemophilia A and inhibitors to factor VIII.

At this interim analysis after a median of 12 weeks of treatment, emicizumab prophylaxis showed a clinically-meaningful reduction in the number of bleeds over time, results which are consistent with findings from the Phase III HAVEN 1 study in adults and adolescents with hemophilia A and inhibitors to factor VIII.

In the earlier study the treatment also showed a statistically-significant and clinically-meaningful reduction in the number of bleeds over time compared to no prophylaxis, as well as compared to prior prophylaxis with bypassing agents.